At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 250 enrolled
Drug / intervention
Lidocaine 8mg + CPC 2mg +1 moredrug
Likely dose
Lidocaine 8mg + CPC 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel Group, Single-dose Study of the Efficacy of Lidocaine 8 mg + Cetylpyridinium Chloride (CPC) 2 mg Fixed Combination Lozenges on Sore Throat Pain Intensity Compared to Lozenges Containing Lidocaine 1 mg and CPC 2 mg in Subjects With Sore Throat Due to Upper Respiratory Tract Infection.
In Brief
A Phase 3 clinical trial evaluating Lidocaine 8mg + CPC 2mg and Lidocaine 1mg + CPC 2mg for Sore Throat Due to a Common Cold. Completed, enrolled 250 participants across 1 site.
Detailed Summary
This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSore Throat Due to a Common Cold
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedDec 23, 2010
Enrollment StartDec 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.5 years ago
Interventions
Lidocaine 8mg + CPC 2mgdrug
one single dose
Lidocaine 1mg + CPC 2mgdrug
one single dose